tipifarnib has been researched along with Atherogenesis in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benchitrit, J; Drüeke, TB; Edelman, A; Galmiche, A; Guerrera, IC; Guillonneau, F; Ivanovski, O; Joki, N; Lacour, B; Lucas, A; Maizel, J; Marçon, F; Massy, ZA; Nguyen-Khoa, T; Nikolov, IG; Phan, O | 1 |
1 other study(ies) available for tipifarnib and Atherogenesis
Article | Year |
---|---|
Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice.
Topics: Animals; Aorta; Apolipoproteins E; Apoptosis; Atherosclerosis; Blood Proteins; Body Weight; Collagen Type I; Enzyme Inhibitors; Farnesyltranstransferase; Female; Kidney Failure, Chronic; Liver; Macrophages; Mevalonic Acid; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Prenylation; Quinolones; Random Allocation; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tyrosine; Uremia; Vascular Calcification | 2013 |